You can buy or sell APTO and other stocks, options, ETFs, and crypto commission-free!
Aptose Biosciences, Inc. Common Shares, also called Aptose Biosciences, is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Read More Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMay 8
Aptose Biosciences Inc. (APTO) CEO William Rice on Q1 2019 Results - Earnings Call Transcript
Yahoo FinanceMay 7
Aptose Biosciences: 1Q Earnings Snapshot
TORONTO (AP) _ Aptose Biosciences Inc. (APTO) on Tuesday reported a loss of $5.5 million in its first quarter. The Toronto-based company said it had a loss of 14 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share. Scroll to continue with content Ad In the final minutes of trading on Tuesday, the company's shares hit $2.23. A year ago, they were trading at $3.28. _____ This story...
Expected Aug 6, After Hours